NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 258,100 shares, a drop of 32.6% from the October 31st total of 383,000 shares. Based on an average daily volume of 237,200 shares, the short-interest ratio is currently 1.1 days. Approximately 1.8% of the company’s stock are short sold.

NeuroSense Therapeutics Trading Up 5.4 %

NASDAQ NRSN traded up $0.05 during trading hours on Friday, reaching $0.98. 323,423 shares of the company traded hands, compared to its average volume of 144,181. NeuroSense Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.33. The stock has a market capitalization of $13.40 million, a PE ratio of -1.15 and a beta of 1.58. The company has a 50 day moving average of $1.17 and a two-hundred day moving average of $1.04.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. XTX Topco Ltd purchased a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned about 0.24% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.